VERIGRAFT

Personalized Transplants

Personalized tissue-engineered organs that will revolutionize future medicine

Petter Björquist, CEO

Disclaimer

The information contained in this document may not be reproduced, distributed or published by any recipient for any purpose without prior written consent. The distribution of this document may be restricted in certain jurisdictions. It is the responsibility of any person or persons in possession of this document to inform themselves of, and to observe, all applicable laws and regulations of any relevant jurisdiction. This document is not intended for distribution to, or use by any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.

This document is intended only for information purposes and convenient reference and does not constitute or form part of any offer to issue or sell, or any solicitation or any offer to subscribe or purchase, any investment nor shall it or the fact of its distribution form the basis of, or be relied on in connection with, any contract therefore. The descriptions contained in this document are a summary and are not intended to be complete. Opinions contained in this document are for background purposes only and do not constitute investment advice. After this document has been published, the facts can change and developments inside or outside VERIGRAFT AB may influence the actual situation.

No reliance may be placed for any purpose on the information and opinions contained in this document or their accuracy or completeness. The information and this information is not intended to provide and should not be relied upon for accounting, legal or tax advice or investment recommendations. Recipients should consult their tax, legal, accounting or other advisors about the issues discussed herein. No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained in this document by VERIGRAFT AB, its members, employees or affiliates and no liability is accepted by such persons for the accuracy or completeness of any such information or opinions, and nothing contained herein shall be relied upon as a promise or representation whether as to past or future performance

- **Founded as a University spin-off from the Karolinska Institute in Stockholm**
- **Head quarter and operations in Biotech Center in Gothenburg, Sweden**
- **Privately funded biotech company**
- **Highly experienced and dedicated team**

Advanced therapies – From nothing to one of medicines most promising fields





Personalized grafts will revolutionize future medicine

A Solution to the Challenges in Transplantation

Heart and liver transplantation is common today, but there are big challenges in transplantation:

- Chronic lack of transplantable organs
- Transplantation requires life-long immunosuppression with severe side-effects (e.g. cancer)

-> In vast majority of cases this is TOO MUCH RISK



VERIGRAFT is developing a solution to these problems

- Personalization of transplants
- No immunosuppression required!

The VERIGRAFT Process for Personalization



- **Foreign (allogeneic) becomes own (autologous)**
- **No Immunosuppression**

Large animal studies confirm safety and efficacy



VERIGRAFT personalized grafts in pig models (5 weeks, 6 months, 12 months) became biologically integrated and remained patent. No rejection of the transplant occurred.

Long term safety of P-TEV in porcine model

P-TEV grafts are open and patent one-year post-integration. There are no signs of thrombosis, rejection, infection of mechanical failure in any of the animals.



Angiography





CD31 staining

Our first indication

Chronic venous insufficiency

- **Valves in deep veins do not work**
- **Swollen legs, pain, non-healing ulcers**
- **1% of the population has CVI**

Huge unmet medical need

- **No cure, only symptomatic treatments on the market**
- **Allotransplantation is not possible due to rejection**





Normal Function





Insufficient Valve

P-TEV Product



Personalized Tissue-Engineered Vein

P-TEV

- 4-6 cm long vein segment
- Contains one functional valve
- Grafting by simple end to end anastomosis

P-TEV for CVI - Continuous Pusatile Valve Testing



More than 500 000 cycles.

TECVI-1 first-in-man clinical trial

VERIGRAFT

Phase I/II clinical trial in Europe

- 15 Patients with severe CVI
- Replacement surgery
- Open vein segment with incompetent valve
- Graft P-TEV with functional valve
- Safety endpoints evaluated after 4 weeks
- Safety and efficacy at 3, 6 and 12 months



First clinical trial of its kind worldwide is now ongoing!

TECVI-1 trial is started

First patient implanted with P-TEV graft

- First patient included in TECVI-1 clinical trial in December 2021
- P-TEV implantation surgery performed January 2022
- Four-weeks safety evaluation performed February 2022; no safety concerns identified
- Three-month safety evaluation performed April 2022; no safety concerns identified
- The valve is functional, and the patient's clinical status is improved
- Staggered inclusion now continues
- 15 patients will be included in TECVI-1 during 2022

The CVI Market

- Huge costs associated with CVI patients
- ATMP on the EU market, expanding to USA
- Strong reimbursement model
- No competition and no other cure in development

Venous Ulcers – Big Five and US Annually
1 Million Suffering
Billion € Market

Upcoming VERIGRAFT Products: P-TEA & P-TEN

Personalized Tissue-Engineered Arteries (P-TEA):

- Safe and efficacious in large animals
- Peripheral and cardiac bypass grafting
- Clinical trials to be started within 2-3 years



Personalized Tissue-Engineered Nerves (P-TEN):

- Large animal study in sheep recently finished
- Positive data confirm peripheral nerve repair

Both products are addressing multi-billion EUR markets!

Scaffolds

Today	**Donated human tissue** Decellularization
Next	**Xenogeneic tissue** Decellularization
Then	**3D printed ECM scaffolds**

Platform for the personalization of xenogeneic and 3D printed tissue scaffolds

Financial support to VERIGRAFT

- **EU Horizon 2020 SME Instrument (2017-2019, Euro 2,2M):**
  Clinical trial program (P-TEV for treatment of chronic venous insufficiency)
- **EU Eurostars (2016-2020, Euro 0,5M):**
  Tissue engineered and personalized nerves for use in regenerative medicine
- **EU Marie Curie (2017-2020, Euro 0,2M):**
  A PhD-student financed to work with personalized tissue engineered blood vessels
- **Swedish foundation grant (2019-2021, Euro 0,24M):**
  Proteomics analysis of personalized tissue engineered blood vessels
- **EU Eurostars (2021-2023, Euro 0,4M):**
  Tissue engineered personalized arteries for use in regenerative medicine
- **Swedish governmental grant (2022-2024, Euro 0,2M):**
  Platform for the personalization of xenogeneic and 3D printed tissue scaffold

Contact Us

VERIGRAFT

info@verigraft.com

Arvid Wallgrens Backe 20
413 46 Gothenburg
Sweden